TY  - JOUR
AU  - Hanefeld, Markolf
AU  - Arteaga, Juan M
AU  - Leiter, Lawrence A
AU  - Marchesini, Giulio
AU  - Nikonova, Elena
AU  - Shestakova, Marina
AU  - Stager, William
AU  - Gómez-Huelgas, Ricardo
PY  - 2017
DO  - 10.1111/dom.12986
UR  - http://hdl.handle.net/10668/11141
T2  - Diabetes, obesity & metabolism
AB  - This post hoc assessment evaluated the efficacy and safety of once-daily, prandial glucagon-like peptide-1 receptor agonist lixisenatide in patients with type 2 diabetes (T2D) and normal renal function (estimated glomerular filtration rate...
LA  - en
PB  - Wiley
KW  - GLP-1
KW  - Incretin therapy
KW  - Meta-analysis
KW  - Type 2 diabetes
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Clinical Trials as Topic
KW  - Diabetes Mellitus, Type 2
KW  - Diabetic Nephropathies
KW  - Female
KW  - Glomerular Filtration Rate
KW  - Humans
KW  - Male
KW  - Middle Aged
KW  - Peptides
KW  - Renal Insufficiency
KW  - Severity of Illness Index
KW  - Treatment Outcome
TI  - Efficacy and safety of lixisenatide in patients with type 2 diabetes and renal impairment.
TY  - research article
VL  - 19
ER  -